These results suggest that, in addition to PD-L1 and prior use of broad-spectrum antimicrobials, MetS is an independent prognostic factor in patients with advanced lung cancer treated with immune checkpoint inhibitors +/- chemotherapy. This evidence concerns the gene CD274 and lung cancer.